How do you decide what to use for 2nd line treatment of liver-predominant metastatic neuroendocrine tumor that has progressed on a somatostatin analog?

Following progression on an SSA, there are a number of options and they differ depending on primary site and whether or not the tumor is functional (ie. secreting a hormone that causes symtoms of hormone excess. I will outline some scenarios below:

1) For patients with non-functional liver-predominan...